Nucleome Therapeutics Limited
- Biotech or pharma, therapeutic R&D
Nucleome is a post-series A biotechnology company based in Oxford, UK. We are using our proprietary technology to decipher human disease genetics to discover new drugs for inflammation. Our lead, genetically validated, asset is NTP464, an antibody that enhances the function of T-regulatory cells to reset the immune system in rheumatoid arthritis (RA) and other autoimmune indications. Our approach is mechanistically distinct from all standard-of-care and promises to be a superior alternative to existing 3rd line drugs in RA. We will initiate clinical trials at the start of 2027. In addition to NTP464, we have developed a pipeline of antibody therapeutics against genetically validated targets, including NTP206.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}